Drug Profile
Levodopa/carbidopa extended release - EPIRUS Biopharmaceuticals
Alternative Names: Levodopa-carbidopa XR - Spherics; SRx-501Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Spherics
- Developer EPIRUS Biopharmaceuticals
- Class Antiasthmatics; Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
- Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
- 17 Jul 2014 Discontinued - Phase-II for Parkinson's disease in Germany (PO)
- 15 Jul 2014 Zalicus has merged with EPIRUS Biopharmaceuticals